Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.

Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). The company will now assume end-to-end responsibility for manufacturing and commercialization, moving beyond its previous role of just commercialization. This strategic shift is designed to improve cost efficiencies and provide greater flexibility in global markets. While Biocon will pay license fees and royalties, FKB will offset certain development costs, supporting the product's long-term growth.

Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.

ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash payment, making BBL a wholly-owned subsidiary. To fund the cash component and repay existing structured debt, Biocon plans a QIP of up to Rs. 4,500 crore. This restructuring aims to simplify the group's corporate structure and consolidate BBL, which contributed 58% of consolidated revenues in FY2025.

ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.

Biocon Limited has launched its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. Liraglutide was approved for medical use in the European Union in 2009.

Biocon Biologics has signed a settlement and license agreement to commercialize biosimilar Aflibercept (YESAFILI) worldwide. This agreement with Regeneron and Bayer covers Europe and the rest of the world, following a previous settlement for the US and Canada. YESAFILI is a VEGF inhibitor used for ophthalmology conditions. The company plans to launch YESAFILI in the UK in January 2026 and in other settled countries by March 2026 or earlier.

Indian Oil Corporation (IOC) has declared an interim dividend of Rs 5 per share for the financial year 2025-26. The company has fixed December 18, 2025, as the record date to determine shareholder eligibility for the payout. Tax will be deducted at source (TDS) at a rate of 10% for resident shareholders with a valid PAN, provided the total dividend for the year exceeds Rs 10,000. Shareholders must submit necessary tax exemption documents like Form 15G/15H by December 17, 2025, to avoid higher tax deductions.

Indian Oil Corporation Limited (IOC) has announced an interim dividend of ₹5.00 per equity share with a face value of ₹10 each for the financial year 2025-26. This dividend represents 50% of the face value. The payment will be made on or before January 11, 2026, to eligible shareholders. The record date for determining eligibility is December 18, 2025.

Music Broadcast Limited (RADIOCITY) announced that the Madras High Court allowed the company's appeals and set aside prior orders related to contempt petitions. The court's decision eliminates the requirement to deposit 50% of alleged royalty dues and furnish historical music-play logs. The High Court held that contempt jurisdiction was not maintainable, as the underlying order is under consideration by the Supreme Court and the monetary liability is unquantified. Consequently, the company anticipates no financial impact from the overturned contempt orders.

S&P Global Ratings has placed Biocon Biologics on 'CreditWatch Positive' following a major restructuring plan to make it a 100% subsidiary of Biocon Limited. The company aims to reduce its adjusted debt significantly from INR 248 billion in March 2025 to approximately INR 120 billion by March 2026. This reduction will be driven by swapping $1 billion in debt-like CCPS held by Viatris for equity and cash, alongside a planned INR 45 billion fresh equity issuance. The move simplifies the capital structure and eliminates minority put options that were previously viewed as debt-like obligations.

Biocon Limited has announced a major consolidation plan to acquire the remaining 23.3% minority stake in Biocon Biologics, making it a 100% subsidiary. The transaction involves a $773 million share swap (171.3 million shares at ₹405.78 each) and a $400 million cash payment to Viatris. This move is designed to simplify the corporate structure, eliminate the holding company discount, and improve financial metrics, with a proforma Net Debt/EBITDA ratio of 2.5x. The company expects the transaction to be completed by Q4 FY2026, following a shareholder vote on December 31, 2025.

Biocon Limited's board approved raising up to ₹4,500 Crores through various means to fund the cash consideration payable to Mylan. The company will also acquire equity shares of Biocon Biologics Limited (BBL) from multiple shareholders, including Mylan, Serum Institute, Tata Capital, and Activ Pine. As part of this acquisition, Biocon will issue 17,12,79,553 equity shares on a preferential basis, amounting to ₹6,950 Crores, for consideration other than cash. The board also approved an increase in authorized share capital from ₹700 Crores to ₹900 Crores.

Biocon Limited will hold an analyst call on December 8, 2025, to discuss Biocon Biologics Limited’s integration with Biocon Limited. The acquisition of minority shareholder stake of 23.3% in Biocon Biologics will be funded through issuance of 171.3 MM equity shares in Biocon Limited and cash consideration of $400MM. The share swap ratio is 61.70 shares of Biocon for every 100 shares of BBL for BBL Shareholders. The transaction is expected to be completed by Q4 FY2026.

Biocon Limited will fully integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary. Biocon will acquire the remaining stake in BBL from Serum, Tata Capital, and Activ Pine through a share swap of 70.28 Biocon shares for every 100 BBL shares, valuing BBL at USD 5.5 billion. Additionally, Biocon will acquire Viatris' stake for USD 815 million, including USD 400 million in cash and USD 415 million in shares. Biocon plans to raise up to ₹4500 crore (USD 500 million) through QIP to fund the cash component.

Biocon's board has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from Mylan, Serum Institute, and others to achieve full integration. The deal involves a preferential share issuance of 17.13 crore shares worth ₹6,950 crore as a swap and a separate cash consideration for Mylan. To fund the cash component, Biocon plans to raise up to ₹4,500 crore through QIP or other routes, supported by an interim ₹1,800 crore commercial paper issuance. This consolidation aims to simplify the corporate structure and create a unified capital allocation strategy by March 2026.

Biocon Limited's wholly-owned subsidiary, Biocon Pharma Limited, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for its ANDA for Carbidopa and Levodopa Extended-Release Capsules. The capsules are in strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. These capsules are used for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. This approval allows Biocon to potentially enter the market upon patent expiry.